Efficacy of tobacco cessation for improving oral diseases - multicentre trial

Not Applicable

• Conditions: Periodontitis Patients for implant treatment Oral mucosal diseases (nicotine stomatitis, oral leukoplakia, erythloplakia and oral lichen planus); Oral Diseases

• Registration Number: JPRN-UMIN000021429
• Lead Sponsor: Tobacco Cessation Intervention Study Team for Oral Diseases (TISOD)

Brief Summary

74 dental patients for enrolment in the trial. The self-reported tobacco abstinence rate in the intervention group was 62.3% at month 3, 42.6% at month 6, and 41.0% at month 12; however, the respective biochemically confirmed abstinence rates were 37.7%, 34.4%, and 32.8%. The patients receiving implant treatment achieved the highest rate of biochemically confirmed tobacco cessation at 42.9% at month 12, followed by 37.1% in those with OPMD and 21.1% in those with periodontitis.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-04-01
• Study Completion: 2019-12-31
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

Not provided

Exclusion Criteria

Less than 20 years old Already having any cessation intervention Having had periodontal treatment within 6 months Periodontitis patients who have anti-inflammatory drug or steroid use Patients for implant treatment; N/A Oral mucosal diseases; have had surgical resections before or other interventional treatments In case of use of nicotine replacement therapy (NRT);already have a prescription of NRTs or medicines, pregnant and breastfeeding women, has unstable angina pectoris, in the immediate (within 3 months) past myocardial infarction period, have serious arrhythmias, post-percutaneous coronary intervention (PCI), post-coronary artery bypass graft (CABG), early period of recovery from cerebrovascular disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified